News | February 14, 2025
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
EDQM has also issued a Certificate of Suitability for Allopurino
The company recently received CEP certificate approval for Losartan Potassium by EDQM
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Subscribe To Our Newsletter & Stay Updated
